aminoimidazole carboxamide has been researched along with Granulocytic Leukemia, Chronic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, HT; Liu, W; Tang, L; You, Y; Zhu, XJ; Zhu, XY; Zou, P | 1 |
| Auberger, P; Belhacene, N; Ben Sahra, I; Bost, F; Cassuto, JP; Colosetti, P; Gounon, P; Hofman, P; Puissant, A; Robert, G | 1 |
| Altman, JK; Donato, NJ; Glaser, H; Platanias, LC; Vakana, E | 1 |
3 other study(ies) available for aminoimidazole carboxamide and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
AICAR and Decitabine Enhance the Sensitivity of K562 Cells to Imatinib by Promoting Mitochondrial Activity.
Topics: Aminoimidazole Carboxamide; Apoptosis; Cell Line, Tumor; Cell Proliferation; Decitabine; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Protein Kinase Inhibitors; Ribonucleotides | 2020 |
Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Protein Kinase C; Ribonucleosides; RNA, Small Interfering; Translocation, Genetic | 2009 |
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.
Topics: Amino Acid Substitution; Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Line, Transformed; Cell Survival; Cell Transformation, Neoplastic; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metformin; Molecular Targeted Therapy; Mutant Proteins; Prodrugs; Protein Kinases; Recombinant Proteins; Ribonucleotides | 2011 |